Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. The company sells its products directly to hospitals or office-based labs. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:CSII
CUSIP14161910
Phone651-259-1600
Debt
Debt-to-Equity Ratio0.17
Current Ratio4.46
Quick Ratio3.99
Price-To-Earnings
Trailing P/E Ratio1,067.00
Forward P/E RatioInfinity
P/E GrowthN/A
Sales & Book Value
Annual Sales$204.91 million
Price / Sales5.20
Cash Flow$0.1574 per share
Price / Cash203.42
Book Value$3.62 per share
Price / Book8.84
Profitability
EPS (Most Recent Fiscal Year)$0.03
Net Income$-1,790,000.00
Net Margins-0.59%
Return on Equity-1.03%
Return on Assets-0.65%
Miscellaneous
Employees579
Outstanding Shares33,260,000
Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions
What is Cardiovascular Systems' stock symbol?
Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."
How were Cardiovascular Systems' earnings last quarter?
Cardiovascular Systems Inc (NASDAQ:CSII) posted its earnings results on Wednesday, May, 2nd. The medical device company reported $0.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.03. The medical device company had revenue of $55.59 million for the quarter, compared to analysts' expectations of $55.63 million. Cardiovascular Systems had a negative return on equity of 1.03% and a negative net margin of 0.59%. View Cardiovascular Systems' Earnings History.
When is Cardiovascular Systems' next earnings date?
What price target have analysts set for CSII?
6 Wall Street analysts have issued 12 month price targets for Cardiovascular Systems' shares. Their predictions range from $23.00 to $30.00. On average, they anticipate Cardiovascular Systems' stock price to reach $26.50 in the next year. View Analyst Ratings for Cardiovascular Systems.
What are Wall Street analysts saying about Cardiovascular Systems stock?
Here are some recent quotes from research analysts about Cardiovascular Systems stock:
- 1. Needham & Company LLC analysts commented, "CSII’s F3Q18 revenue met consensus while EPS beat consensus. Management’s F4Q18 revenue guidance bracketed consensus while EPS guidance was above consensus. The F4Q18 revenue guidance requires a substantial acceleration from F3Q18 but we note that CSII faces a significantly easier revenue growth comp in F4Q18 than in F3Q18 (9.2% vs. 17.3%). Looking into FY19, CSII should continue to benefit from the Japanese launch, new support products, building rep productivity, and a further easing of comps so we think it can see its revenue growth accelerate further. However, it remains to be seen if CSII can sustain double- digit revenue growth and considering its 3.0x 2018E EV/sales multiple, we maintain our Hold rating." (5/3/2018)
- 2. According to Zacks Investment Research, "Cardiovascular Systems exited second-quarter fiscal 2018 on a solid note with year-over-year increase in revenues at both CAD and PAD businesses. Also, the expansion is gross margin was impressive. Moreover, the company is putting efforts in product innovation through R&D investments. The market is also looking forward to the recently-launched coronary device in Japan, reflecting the company’s focus on international expansion. On the flip side, Cardiovascular Systems faces cutthroat competition in the niche space. Coming to profitability, Cardio Vascular incurred net loss in the recently-reported second quarter. In fact, the company has a long history of net losses since inception. Also, the lowered revenue guidance for fiscal 2018 is discouraging. Over the past year, Cardiovascular Systems has been trading below the broader industry." (2/12/2018)
Are investors shorting Cardiovascular Systems?
Cardiovascular Systems saw a decrease in short interest in May. As of May 15th, there was short interest totalling 870,547 shares, a decrease of 35.1% from the April 30th total of 1,340,725 shares. Based on an average daily volume of 308,681 shares, the days-to-cover ratio is currently 2.8 days. Approximately 2.7% of the shares of the company are short sold.
Who are some of Cardiovascular Systems' key competitors?
Some companies that are related to Cardiovascular Systems include Cantel Medical (CMD), NuVasive (NUVA), Novocure (NVCR), Merit Medical Systems (MMSI), Nevro (NVRO), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Glaukos (GKOS), Luminex (LMNX), Orthofix International (OFIX), OraSure Technologies (OSUR), Intersect ENT (XENT), Atrion (ATRI), Cryolife (CRY) and Tactile Systems Technology (TCMD).
Who are Cardiovascular Systems' key executives?
Cardiovascular Systems' management team includes the folowing people:
- Mr. Scott Raymond Ward MS, B.Sc., Chairman, Chief Exec. Officer and Pres (Age 58)
- Mr. Laurence L. Betterley, VP of Admin. (Age 64)
- Ms. Laura J. Gillund, Chief Talent Officer (Age 57)
- Mr. Jeffrey S. Points, Chief Financial Officer
- Ms. Rhonda J. Robb, Chief Operating Officer
Has Cardiovascular Systems been receiving favorable news coverage?
Media coverage about CSII stock has been trending somewhat negative on Wednesday, according to Accern Sentiment. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cardiovascular Systems earned a news impact score of -0.02 on Accern's scale. They also gave media headlines about the medical device company an impact score of 40.10 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Cardiovascular Systems' major shareholders?
Cardiovascular Systems' stock is owned by a number of of retail and institutional investors. Top institutional investors include Champlain Investment Partners LLC (7.79%), BlackRock Inc. (6.82%), Cortina Asset Management LLC (2.53%), Frontier Capital Management Co. LLC (2.37%), New York State Common Retirement Fund (1.62%) and First Light Asset Management LLC (1.41%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Camber Capital Management Llc, Edward M Brown, Jeffrey S Points, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Paul A Koehn and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.
Which major investors are selling Cardiovascular Systems stock?
CSII stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Hussman Strategic Advisors Inc., Schwab Charles Investment Management Inc., New York State Common Retirement Fund, A.R.T. Advisors LLC, Northern Trust Corp, Wells Fargo & Company MN and Frontier Capital Management Co. LLC. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, Edward M Brown, Jeffrey S Points, Kevin J Kenny, Laura Gillund, Laurence L Betterley and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.
Which major investors are buying Cardiovascular Systems stock?
CSII stock was acquired by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Point72 Asset Management L.P., Cortina Asset Management LLC, Russell Investments Group Ltd., Citadel Advisors LLC, Dynamic Technology Lab Private Ltd, First Light Asset Management LLC and Thomson Horstmann & Bryant Inc.. View Insider Buying and Selling for Cardiovascular Systems.
How do I buy shares of Cardiovascular Systems?
Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cardiovascular Systems' stock price today?
One share of CSII stock can currently be purchased for approximately $32.01.
How big of a company is Cardiovascular Systems?
Cardiovascular Systems has a market capitalization of $1.06 billion and generates $204.91 million in revenue each year. The medical device company earns $-1,790,000.00 in net income (profit) each year or $0.03 on an earnings per share basis. Cardiovascular Systems employs 579 workers across the globe.
How can I contact Cardiovascular Systems?
Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]
MarketBeat Community Rating for Cardiovascular Systems (CSII)
MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe CSII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSII will underperform the S&P 500 over the long term. You may vote once every thirty days.
